Abstract:The COVID-19 pandemic was caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Here, we use enhanced crosslinking and immunoprecipitation to investigate SARS-CoV-2 protein interactions with viral and host RNAs. SARS-CoV-2 proteins, NSP8 and NSP12, bind to specific regions in the RNA viral genome, providing evidence for their central and potential roles in replication, transcription and genome recombination. SARS-CoV-2 proteins expressed in human lung epithelial cells bind to 4,821 unique host RNAs. Nine SARS-CoV-2 proteins upregulate target gene expression, including NSP12 which upregulates mitochondrial and N-linked glycosylation proteins. Furthermore, siRNA knockdown of host genes targeted by the viral proteins in human lung organoid cells demonstrates substantial antiviral effects. Conversely, NSP9 inhibits host gene expression by blocking mRNA export and dampens inflammatory responses such as interleukin-1α/β production. Our extensive viral protein-RNA interactome provides a catalog of potential therapeutic targets and offers insight into the etiology of COVID-19 as a safeguard against future pandemics.Funding Information: The work has been supported by Emergency COVID-19 Research Seed Funding (#R00RG2636) from the University of California Office of the President. This publication includes data generated at the UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929). J.S.X as a visiting fellow is partially supported by Agency for Science, Technology and Research (A*STAR) and Industrial Alignment Fund Pre-Positioning (IAF-PP) grant H17/01/a0/012. ELVN is supported by the NHGRI (R00HG009530).Declaration of Interests: J.S.X, F.E.T, J.C.S and G.W.Y declare a pending patent application. ELVN is co-founder, member of the Board of Directors, on the SAB, equity holder, and paid consultant for Eclipse BioInnovations. ELVN’s interests have been reviewed and approved by the Baylor College of Medicine in accordance with its conflict of interest policies. The authors declare no other competing interestsEthics Approval Statement: This study protocol was approved by the Institutional Review Board of UCSD's Human Research Protections Program (181180).

Computational Identification of Small Interfering RNA Targets in SARS-CoV-2

Construction and Investigation of Competing Endogenous RNA Networks and Candidate Genes Involved in SARS-CoV-2 Infection

Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus

In Vivo Structural Characterization of the SARS-CoV-2 RNA Genome Identifies Host Proteins Vulnerable to Repurposed Drugs.

SARS2020: an integrated platform for identification of novel coronavirus by a consensus sequence-function model

Characterization and functional interrogation of the SARS-CoV-2 RNA interactome

Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection

Discovery and Functional Interrogation of the Virus and Host RNA Interactome of SARS-Cov-2 Proteins

Identification, characterization and expression analysis of circRNA encoded by SARS-CoV-1 and SARS-CoV-2

The short- and long-range RNA-RNA Interactome of SARS-CoV-2

Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection

Identification of Cellular Factors Required for SARS-CoV-2 Replication

Human MicroRNAs Interacting With SARS-CoV-2 RNA Sequences: Computational Analysis and Experimental Target Validation

Changes of Small Non-coding RNAs by Severe Acute Respiratory Syndrome Coronavirus 2 Infection

SARS-CoV-2 orthologs of pathogenesis-involved small viral RNAs of SARS-CoV

Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions

Identification of the viral and cellular microRNA interactomes during SARS-CoV-2 infection

Meta-transcriptomic analysis reveals the gene expression and novel conserved sub-genomic RNAs in SARS-CoV-2 and MERS-CoV

Identification of potent small molecule inhibitors of SARS-CoV-2 entry

An ncRNA transcriptomics-based approach to design siRNA molecules against SARS-CoV-2 double membrane vesicle formation and accessory genes

Competitive Endogenous RNA Network Activates Host Immune Response in SARS-CoV-2-, panH1N1 (A/California/07/2009)-, and H7N9 (A/Shanghai/1/2013)-Infected Cells